drugset / Trial / NCT00171743

Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

NCT00171743

Phase 4 Completed 47 enrolled Novartis
Non-randomizedFactorialOpen-labelPrevention

Summary

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Timeline

Start
2004-04
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide

Indications

No indication recorded.